文献速递头颈部肿瘤放疗

间充质干细胞治疗放射性口干症的安全性与疗效:随机安慰剂对照1/2期试验(MESRIX)

Safety and Efficacy of Mesenchymal Stem Cells for Radiation-Induced Xerostomia: A Randomized, Placebo-Controlled Phase 1/2 Trial (MESRIX).
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-03-06

这项随机、安慰剂对照1/2期试验纳入30例曾接受头颈放疗的HPV阳性口咽鳞癌患者,1:1接受超声引导下脂肪来源间充质干细胞(ASC)或安慰剂移植至颌下腺。结果显示ASC组未刺激全唾液流率在1个月(33%,P=.048)和4个月(50%,P=.003)显著增加,安慰剂组无变化;ASC组口干症状评分显著改善,无不良事件。结论认为ASC治疗放射性口干安全且有效。

要点

  • ASC组未刺激全唾液流率1个月增加33%(P=.048),4个月增加50%(P=.003)。
  • ASC组口渴症状评分4个月下降22%(P=.035),进食固体食物困难下降2%(P=.008)。
  • ASC组活检显示浆液腺组织增加、脂肪和结缔组织减少(P=.04和P=.02)。

核心结论

  • ASC治疗放射性唾液腺功能减退和口干症是安全的,并显著改善唾液腺功能和患者报告结局。
  • 结果支持进一步开展探索性和确证性试验。

研究设计与样本

  • 随机、安慰剂对照1/2期试验,纳入30例曾接受放疗的T1-2、N0-2A、HPV阳性口咽鳞癌患者。
  • 患者按1:1随机接受超声引导下ASC或安慰剂移植至颌下腺。
  • 主要终点为干预前后未刺激全唾液流率的变化,评估在基线(干预前1个月)及干预后1个月和4个月进行。

主要发现

  • 未检测到不良事件。
  • ASC组未刺激全唾液流率较基线显著增加:1个月增加33%(P=.048),4个月增加50%(P=.003);安慰剂组无显著变化(P=.6和P=.8)。
  • ASC组口干问卷和VAS问卷症状评分显著下降:4个月时口渴域下降22%(P=.035),进食固体食物困难域下降2%(P=.008)。
  • ASC组无机元素分泌和吸收的唾液腺功能在基线和4个月时较安慰剂组显著改善。
  • 粗针活检显示ASC组较安慰剂组浆液腺组织增加、脂肪和结缔组织减少(P=.04和P=.02);MRI显示两组腺体大小或强度无显著差异(P<.05)。

临床怎么用

  • 对于曾接受头颈放疗的HPV阳性口咽鳞癌患者,颌下腺ASC移植可能安全改善唾液流率和口干症状。
  • 症状评估可关注口渴和进食固体食物困难等口干相关域。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Salivary gland hypofunction and xerostomia are major complications to head and neck radiotherapy. This trial assessed the safety and efficacy of adipose tissue-derived mesenchymal stem cell (ASC) therapy for radiation-induced xerostomia. PATIENT AND METHODS: This randomized, placebo-controlled phase 1/2 trial included 30 patients, randomized in a 1:1 ratio to receive ultrasound-guided transplantation of ASCs or placebo to the submandibular glands. Patients had previously received radiotherapy for a T1-2, N0-2A, human papillomavirus-positive, oropharyngeal squamous cell carcinoma. The primary outcome was the change in unstimulated whole salivary flow rate, measured before and after the intervention. All assessments were performed one month prior (baseline) and one and four months following ASC or placebo administration. RESULTS: No adverse events were detected. Unstimulated whole salivary flow rates significantly increased in the ASC-arm at one (33%; P = .048) and four months (50%; P = .003), but not in the placebo-arm (P = .6 and P = .8), compared to baseline. The ASC-arm symptom scores significantly decreased on the xerostomia and VAS questionnaires, in the domains of thirst (-22%, P = .035) and difficulties in eating solid foods (-2%, P = .008) after four months compared to baseline. The ASC-arm showed significantly improved salivary gland functions of inorganic element secretion and absorption, at baseline and four months, compared to the placebo-arm. Core-needle biopsies showed increases in serous gland tissue and decreases in adipose and connective tissues in the ASC-arm compared to the placebo-arm (P = .04 and P = .02, respectively). MRIs showed no significant differences between groups in gland size or intensity (P < .05). CONCLUSIONS: ASC therapy for radiation-induced hypofunction and xerostomia was safe and significantly improved salivary gland functions and patient-reported outcomes. These results should encourage further exploratory and confirmatory trials.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Grønhøj C, Jensen DH, Vester-Glowinski P, et al. Safety and Efficacy of Mesenchymal Stem Cells for Radiation-Induced Xerostomia: A Randomized, Placebo-Controlled Phase 1/2 Trial (MESRIX). Int J Radiat Oncol Biol Phys. 2018. PMID: 29678523. doi:10.1016/j.ijrobp.2018.02.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。